I am also having the same problem in both splicing.diff and promotor.diff.
I have 5 samples in each of two groups, but only 25M reads per sample (100bp paired end).
Promoters
Cufflinks 1.0.3
OK 11,309
NOTEST 8,637
FAIL 648
with 7,902 significant
Cuffdiff 1.3
OK 1,383
NOTEST 10,243
FAIL 8,948
2 significant
Splicing
Cufflinks 1.0.3
OK 13,996
NOTEST 51,240
FAIL 2,933
8,645 genes with sig. differential splicing
Cufflinks 1.3
OK 1,017
NOTEST 28,032
FAIL 37,736
LOWDATA 1,401
6 genes with sig. differential splicing.
Unconfigured Ad
Collapse
X
-
New differential testing of cuffdiff/cufflinks since 1.3.0
Hi all,
I have been trying out the new 1.3 version of the cufflinks package to see if the testing for differential splicing/expression etc is improved.
Now I expected a more stringent analysis, as announced, but I get mostly failed tests.
I used the same reads.bam and annotation and the same parameters (5 biological replicates and 2 groups, 2x 100 bp PE reads, ~ 140mil per sample).
This is my result with cuffdiff v1.0.3 for diff. promoter usage:
191 FAIL
13713 NOTEST
4745 OK
with 1403 Genes found with sign. diff. promoter usage.
Now this is the cuffdiff v 1.3 result:
5719 FAIL
35 LOWDATA
12301 NOTEST
594 OK
with 20 Genes found with sign. diff. promoter usage.
It seems that the number of false positives is really reduced. The new version find only ~ 3.5% of genes tested to be differential. However, so many fail to be tested in the first place that the result is not really usable.
Did anyone experience something similar? Is this failing of testing maybe related to my large dataset or the replicates?
All the best,
SebastianTags: None
Latest Articles
Collapse
-
by SEQadmin2
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...-
Channel: Articles
10-14-2026, 09:55 AM -
-
by SEQadmin2
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...-
Channel: Articles
-
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, 10-22-2026, 11:13 AM
|
0 responses
60 views
0 reactions
|
Last Post
by SEQadmin2
10-22-2026, 11:13 AM
|
||
|
Started by SEQadmin2, 10-22-2026, 10:48 AM
|
0 responses
42 views
0 reactions
|
Last Post
by SEQadmin2
10-22-2026, 10:48 AM
|
||
|
Started by SEQadmin2, 10-15-2026, 10:52 AM
|
0 responses
75 views
0 reactions
|
Last Post
by SEQadmin2
10-15-2026, 10:52 AM
|
||
|
Started by SEQadmin2, 10-14-2026, 05:39 AM
|
0 responses
74 views
0 reactions
|
Last Post
by SEQadmin2
10-14-2026, 05:39 AM
|
Leave a comment: